Multiple sclerosis: Diagnosis, management and prognosis

Australian Family Physician

Volumn 40, Issue 12, 2011, Pages 948-955

  Tsang, Benjamin K T ^a   Macdonell, Richard ^a  

^a Austin Hospital   (Argentina)

Author keywords

Multiple sclerosis

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT; MITOXANTRONE;

ADULT; ARTICLE; AUSTRALIA; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; GENERAL PRACTICE; HEALTH STATUS; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; STATISTICS;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTINEOPLASTIC AGENTS; AUSTRALIA; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FAMILY PRACTICE; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; PHYSICIAN'S PRACTICE PATTERNS; YOUNG ADULT;

EID: 84855968696     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hafler DA. Multiple sclerosis. J Clin Invest 2004;113:788-94.
2. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008;255(Suppl 1):3-11.
3. Pender MP. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev 2009;8:563-8.
4. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-9.
5. Simpson S Jr, Pittas F, van der Mei I, Blizzard L, Ponsonby AL, Taylor B. Trends in the epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951 to 2009. J Neurol Neurosurg Psychiatry 2010;82:180-7.
6. Lucas RM, Ponsonby AL, McMichael AJ, et al. Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function. Mult Scler 2007;13:827-39.
7. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis. Part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-8.
8. Lovblad KO, Anzalone N, Dorfler A, et al. MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol 2010;31:983-9.
9. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
10. Shaw C, Chapman C, Butzkueven H. How to diagnose multiple sclerosis and what are the pitfalls. Intern Med J 2009;39:792-9.
11. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-32.
12. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-29.
13. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-5.
14. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005;58:840-6.
15. Schumacker GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: Report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 1965;122:552-68.
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
17. Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 2005;62:1673-80.
18. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993;329:1764-9.
19. Thrower BW. Relapse management in multiple sclerosis. Neurologist 2009;15:1-5.
20. Australian Medicines Handbook. Adelaide, South Australia: Australian Medicines Handbook, 2010.
21. Victorian Drug Usage Advisory Committee. Therapeutic guidelines: Neurology. North Melbourne, Vic.: Therapeutic Guidelines, 2007.
22. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
23. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-85.
24. Tintore M. Rationale for early intervention with immunomodulatory treatments. J Neurol 2008;255(Suppl 1):37-43.
25. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
26. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33.
27. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009;361:1081-7.
28. Available at www.australianprescriber.com/latest_drug/fingolimod%20 hydrochloride%20/948.
29. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40.
30. Kappos L, Radue EW, O'Connor P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
31. Cohen JA, Barkhof F, Comi G, et al; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
32. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004;127(Pt 6):1353-60.
33. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127(Pt 4):844-50.
34. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-6.
35. Tintore M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-72.
36. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-64.
37. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8.
38. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126(Pt 4):770-82.
39. Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol 2011;24:244-9.